Related Experiment Video
Updated: Jun 25, 2026
09:32
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
14.7K
Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1
Elaine Lai-Han Leung1, Run-Ze Li2,3, Xing-Xing Fan4
1Cancer Center, Faculty of Health Sciences; MOE Frontiers Science Center for Precision Oncology, University of Macau, Macau (SAR), China. lhleung@um.edu.mo.
Nature Communications
|August 22, 2023
Summary
Predicting immunotherapy response in non-small cell lung cancer (NSCLC) is crucial. Certain T cell subsets (CD8+ and CD8+CD101hiTIM3+) correlate with poor outcomes, while others indicate better progression-free survival in NSCLC patients receiving anti-PD1 therapy.
Area of Science:
- Immunology
- Oncology
- Translational Medicine
Background:
- Immunotherapy response varies significantly in cancer patients.
- Identifying predictive biomarkers for favorable outcomes in non-small cell lung cancer (NSCLC) is critical for optimizing anti-PD1 therapy.
Purpose of the Study:
- To longitudinally monitor peripheral blood immune cells and cytokines in NSCLC patients undergoing anti-PD1 therapy.
- To identify immunological parameters associated with clinical response to immune checkpoint blockade.
Main Methods:
- High-dimensional cytometry by time of flight (CyTOF) and Meso Scale Discovery (MSD) multi-cytokine assays were used.
- Longitudinal peripheral blood samples from NSCLC patients receiving anti-PD1 therapy were analyzed.
Main Results:
- Higher proportions of circulating CD8+ T cells and CD8+CD101hiTIM3+ (CCT T) subsets correlated with poor clinical response.
- Low frequencies of CD8+ T cells and CCT T cells were observed in responders throughout treatment.
- Higher killer cell lectin-like receptor subfamily G, member 1 (KLRG1) expression on CCT T cells at baseline predicted prolonged progression-free survival.
Conclusions:
- Circulating CD8+ and specific CCT T cell subsets serve as potential biomarkers for predicting anti-PD1 therapy response in NSCLC.
- Immune cell profiling provides insights into the immunological landscape influencing treatment outcomes in lung cancer.
